USFDA inspection: Ipca Labs Piparia facility gets VAI status
Advertisement
Mumbai: Ipca Labs has announced that the United States Food and Drug Administration (USFDA) has determined the inspection classification of the Piparia (Silvassa) formulations manufacturing facility as Voluntary Action Indicated (VAI).
The USFDA had inspected the said facility from 18th April, 2023 to 26th April, 2023 and issued three observations under USFDA Form 483.
Voluntary action indicated (VAI) means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
"Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regards to current good manufacturing practice (CGMP)," the Company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.